172 related articles for article (PubMed ID: 10612649)
1. MHC-restricted protection of cats against FIV infection by adoptive transfer of immune cells from FIV-vaccinated donors.
Pu R; Omori M; Okada S; Rine SL; Lewis BA; Lipton E; Yamamoto JK
Cell Immunol; 1999 Nov; 198(1):30-43. PubMed ID: 10612649
[TBL] [Abstract][Full Text] [Related]
2. An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection.
Aranyos AM; Roff SR; Pu R; Owen JL; Coleman JK; Yamamoto JK
Vaccine; 2016 Mar; 34(12):1480-8. PubMed ID: 26802606
[TBL] [Abstract][Full Text] [Related]
3. Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus.
Dunham SP; Bruce J; Klein D; Flynn JN; Golder MC; MacDonald S; Jarrett O; Neil JC
Vaccine; 2006 Nov; 24(49-50):7095-108. PubMed ID: 17049683
[TBL] [Abstract][Full Text] [Related]
4. Mechanism(s) of FIV vaccine protection.
Pu R; Tellier MC; Yamamoto JK
Leukemia; 1997 Apr; 11 Suppl 3():98-101. PubMed ID: 9209311
[TBL] [Abstract][Full Text] [Related]
5. Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine.
Omori M; Pu R; Tanabe T; Hou W; Coleman JK; Arai M; Yamamoto JK
Vaccine; 2004 Dec; 23(3):386-98. PubMed ID: 15530685
[TBL] [Abstract][Full Text] [Related]
6. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.
Kusuhara H; Hohdatsu T; Okumura M; Sato K; Suzuki Y; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
Vet Microbiol; 2005 Jul; 108(3-4):155-65. PubMed ID: 15899558
[TBL] [Abstract][Full Text] [Related]
7. Feline immunodeficiency virus (FIV)-specific cytotoxic T lymphocytes from chronically infected cats are induced in vitro by retroviral vector-transduced feline T cells expressing the FIV capsid protein.
Song W; Collisson EW; Li J; Wolf AM; Elder JH; Grant CK; Brown WC
Virology; 1995 Jun; 209(2):390-9. PubMed ID: 7778274
[TBL] [Abstract][Full Text] [Related]
8. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination.
Flynn JN; Keating P; Hosie MJ; Mackett M; Stephens EB; Beatty JA; Neil JC; Jarrett O
J Immunol; 1996 Oct; 157(8):3658-65. PubMed ID: 8871667
[TBL] [Abstract][Full Text] [Related]
9. Protection of neonatal kittens against feline immunodeficiency virus infection with passive maternal antiviral antibodies.
Pu R; Okada S; Little ER; Xu B; Stoffs WV; Yamamoto JK
AIDS; 1995 Mar; 9(3):235-42. PubMed ID: 7755911
[TBL] [Abstract][Full Text] [Related]
10. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
[TBL] [Abstract][Full Text] [Related]
11. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates.
Pu R; Coleman J; Omori M; Arai M; Hohdatsu T; Huang C; Tanabe T; Yamamoto JK
AIDS; 2001 Jul; 15(10):1225-37. PubMed ID: 11426067
[TBL] [Abstract][Full Text] [Related]
12. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA.
Lockridge KM; Chien M; Dean GA; Stefano Cole K; Montelaro RC; Luciw PA; Sparger EE
Virology; 2000 Jul; 273(1):67-79. PubMed ID: 10891409
[TBL] [Abstract][Full Text] [Related]
13. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
[TBL] [Abstract][Full Text] [Related]
14. Assessment of CD4+ and CD8+ IFN-gamma producing cells by ELISPOT in naïve and FIV-infected cats.
Sirriyah J; Dean GA; LaVoy A; Burkhard MJ
Vet Immunol Immunopathol; 2004 Nov; 102(1-2):77-84. PubMed ID: 15451617
[TBL] [Abstract][Full Text] [Related]
15. Peptide mapping of feline immunodeficiency virus by IFN-gamma ELISPOT.
Dean GA; LaVoy A; Burkhard MJ
Vet Immunol Immunopathol; 2004 Jul; 100(1-2):49-59. PubMed ID: 15182995
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.
Gupta S; Leutenegger CM; Dean GA; Steckbeck JD; Cole KS; Sparger EE
J Virol; 2007 Jan; 81(2):465-73. PubMed ID: 17079309
[TBL] [Abstract][Full Text] [Related]
17. Alloimmunity does not protect from challenge with the feline immunodeficiency virus.
Reggeti F; Bienzle D
Vet Immunol Immunopathol; 2008 Jul; 124(1-2):152-62. PubMed ID: 18471896
[TBL] [Abstract][Full Text] [Related]
18. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O
AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1107-13. PubMed ID: 8554908
[TBL] [Abstract][Full Text] [Related]
19. Utilization of Feline ELISpot to Evaluate the Immunogenicity of a T Cell-Based FIV MAP Vaccine.
Sahay B; Aranyos AM; McAvoy A; Yamamoto JK
Methods Mol Biol; 2018; 1808():197-219. PubMed ID: 29956186
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of vaccination strategies against infection with feline immunodeficiency virus (FIV) based on recombinant viral vectors expressing FIV Rev and OrfA.
Huisman W; Schrauwen EJ; Tijhaar E; Süzer Y; Pas SD; van Amerongen G; Sutter G; Rimmelzwaan GF; Osterhaus AD
Vet Immunol Immunopathol; 2008 Dec; 126(3-4):332-8. PubMed ID: 18952300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
